FEATURED EDITORIAL
Despite their potential to revolutionize treatment paradigms, antibody-drug conjugates (ADCs) face challenges that companies must tackle for successful development.
- Understanding The Impact Of An RMP On Patient Risks Using Relational Risk Analysis
- Designing The Next Wave Of T Cell Engagers
- AI Vs. Humans In Novel Drug Target Identification
- A Checklist For Mechanism-Based Potency Testing In Cell Therapy
- FDA RIFs Might Delay Your Review — Here Are Tips For Mitigating
- Promising Clinical Trial Updates Shared At The American Academy Of Neurology Conference
- How To Approach Tech Transfers And Sponsored Life Sciences Research In An AI Age
FEATURED APPLICATION CONTENT
-
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
-
Are robotic gloveless isolators the key to smarter, safer, scalable solutions? Discover how they can revolutionize aseptic filling by reducing contamination, minimizing waste, and enhancing manufacturing flexibility.
-
CDMOs must innovate production architectures to meet the demands of advanced therapeutics to ensure a reliable supply and compliance. Discover how these approaches advance modern medicine and improve patient outcomes.
-
Delve into the intricate workflow employed for the discovery and characterization of monoclonal antibodies (mAbs) targeting the Delta spike protein.
-
Overcoming the limitations of current proximity inducers requires optimizing cooperativity. Learn how enhancing target affinity can lead to smaller, more effective therapeutics with better safety profiles.
-
Maximize your research potential by overcoming workflow bottlenecks. This piece explores flexible strategies for increasing throughput and integrating automation seamlessly into your laboratory operations.
-
Continuous processes enhance product quality, yield, and cost savings. Explore transitioning a fed-batch process to perfusion using a small batch bioreactor system to optimize cell culture conditions and comparing performances.
-
Discover how a company overcame cell generation challenges by using a system that achieves a seed ratio of 1:120 and saves four days in seed preparation time.
-
Efforts to enhance biopharmaceutical manufacturing focus on boosting production capacity sustainably and economically. Explore how optimizing processes with single-use solutions and monitoring leachables ensures product quality.
-
Discover the critical role of formulation buffer composition in stabilizing monoclonal antibodies during tangential flow filtration, a process involving ultrafiltration and diafiltration under high pressure and shear forces.
-
Read more about how Fujifilm Diosynth Biotechnologies evaluated a prime filter with challenging simulant solutions and how the experimental data confirmed superior performance, which demonstrated twice the throughput.
-
Explore how tangential flow filtration (TFF) systems streamline lentivirus purification to enhance efficiency and scalability in CAR-T cell production, which is a crucial advancement in cancer immunotherapy.
FEATURED NEWS HEADLINES
- STEERLife Redefines Potent Drug Development With Clean, Green, Continuous Processing
- Clarivate Enhances OFF-X With Pathway Maps To Accelerate Target Safety Assessments
- AbTherx, Single Cell Technology, And Vaccinex Announce Collaboration To Tackle Challenging Antibody Drug Targets
- Comend And Odylia Partner To Advance Rare Disease Drug Development With Innovative Patient-Driven Platform
- CytoTronics Expands Pixel Capability With Multi-Modal Cardiac Application For Early Screening Of Drug Candidates In Cardiovascular Research
- AI Tool Predicts Potential Drug Targets By Analyzing Cell Images
- Thermosome Receives U.S. Orphan Drug Designation For Lead Compound THE001, Expands Patent Estate
- NanoTemper Announces Prometheus Panta C: Powering Biopharma Breakthroughs From Preclinical To Commercial Manufacturing
- Lantern Pharma Secures FDA Clearance For Planned Phase 1b/2 Trial Of LP-184 In Biomarker-Defined, Treatment-Resistant NSCLC Patients With High Unmet Clinical Need
- Cell Death Discovery Could Lead To Next-Gen Drugs For Neurodegenerative Conditions
ARCHIVED NEWSLETTER
- 05.13.25 -- FDA RIFs Might Delay Your Review — Here Are Tips For Mitigating
- 05.06.25 -- Promising Clinical Trial Updates Shared At The American Academy Of Neurology Conference
- 04.29.25 -- FDA Issues Draft Guidance On The Use Of AI To Support Regulatory Decision-Making For Drug And Biological Products
- 04.22.25 -- How To Approach Tech Transfers And Sponsored Life Sciences Research In AI
- 04.18.25 -- Struggling With CDMO Fit, Capacity, Or Delays? Let's Solve These Challenges Together!